Introduction
Retatrutide (LY3437943) is an investigational peptide that was developed by the pharmaceutical company Eli Lilly. Its main characteristics are described as a triple hormone receptor agonist given below:
- GIP
- GLP-1
- Glucagon
Unlike semaglutide (a selective GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist), retatrutide affects the three receptors listed above.
Each of these receptors has a unique function; for instance, GIP and GLP-1 are strongly associated with nutrient sensing, glucose regulation and appetite-related signaling, while glucagon plays a major role in hepatic glucose and energy metabolism. Therefore, this peptide is a valuable tool for scientific research.
The article entitled “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept”, published in the Cell Metabolism journal, provides comprehensive preclinical data concerning the mechanism of action of retatrutide. In vitro, retatrutide showed balanced GCGR and GLP-1R activity, with greater activity at GIPR. This information was obtained through various studies of retatrutide’s pharmacological properties.
Following the preclinical trials, the peptide has undergone clinical investigation and has demonstrated its efficacy and safety. The findings of the study have been published in the New England Journal of Medicine under the title “Triple–Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial”. The Phase 2 trial provided clinical evidence of substantial weight reduction and further characterized retatrutide’s safety and pharmacological effects.
If you are interested in Retatrutide phase 3 clinical results, read our article Breaking: Eli Lilly Retatrutide Phase 3 Results Show Outstanding Weight Loss Data
This article aims to describe the functions of GIP, GLP-1, and glucagon receptors, explain retatrutide’s mode of action, and discuss why it has become a subject of extensive scientific research.
Note: At Orionpeptide, we supply peptides for research purposes.
Retatrutide: An Overview
Retatrutide is an investigational peptide having activity at three hormone receptors. Its triple-agonist profile is the key feature that separates it from other incretin-based compounds.
| Characteristic | Specification |
| Research name | LY3437943 |
| Type of Peptide | Synthetic peptide |
| CAS number | 2381089-83-2 |
| PubChem ID | 171390338 |
| Amino Acid Sequence | YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³ |
| Molecular Weight | 4731.34 g/mol |
| Receptor activity | GIPR, GLP-1R, and GCGR |
| GIP activity | Yes |
| GLP-1 activity | Yes |
| Glucagon activity | Yes |
| Developer | Eli Lilly and Company |
| Research status | Investigational |
| Major research areas | Metabolic and endocrine signaling |
The three receptors belong to the class B1 G protein-coupled receptor (GPCR) family, but they produce different biological signals. GIP and GLP-1 are incretin hormones that respond to nutrient intake, while glucagon plays an important role in glucose and energy metabolism.
The key research interest in retatrutide comes from combining these pathways within one molecule. The discovery study “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” established its activity across the three receptor systems.
Note: Retatrutide is still an investigational compound, so research findings should not be presented as evidence of an FDA-approved treatment.
GIP, GLP-1, and Glucagon: An Overview
It is important to understand the three hormones behind its mechanism before knowing what Retatrutide really is. GIP, GLP-1, and glucagon are naturally occurring signaling hormones with different roles in glucose control, appetite, and energy metabolism.
GIP
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone released by intestinal cells after food intake. Its receptor, GIPR, is found in tissues involved in metabolic regulation. GIP signaling can enhance glucose-dependent insulin secretion and influence energy metabolism.
GLP-1
Glucagon-like peptide-1 (GLP-1) is another incretin hormone released after meals. Its receptor, GLP-1R, participates in glucose-dependent insulin secretion, glucagon regulation, appetite signaling, and gastrointestinal processes. GLP-1 receptor agonists use this pathway as their primary pharmacological target.
Glucagon
Glucagon is a peptide hormone produced mainly by pancreatic alpha cells. Its receptor, GCGR, plays a major role in maintaining glucose availability between meals. Glucagon signaling also influences hepatic metabolism and energy utilization.
The key difference is that these hormones do not perform the same job. GIP and GLP-1 mainly respond to nutrient intake, while glucagon helps regulate glucose and energy availability. Retatrutide is designed to activate the receptors for all three, creating its distinctive triple-agonist profile.
What Happens When These Receptors Are Activated?
GIP, GLP-1, and glucagon receptors belong to the class B1 G protein-coupled receptor (GPCR) family. When their natural hormones, or a receptor-targeting investigational peptide such as retatrutide, bind to these receptors, they trigger intracellular signaling pathways.
A simplified pathway looks like this:
Hormone or peptide → receptor activation → intracellular signaling → cellular response
GIP Receptor
GIPR activation can increase cyclic AMP (cAMP) signaling in responsive cells. In pancreatic beta cells, this pathway supports glucose-dependent insulin secretion. GIP signaling also has broader effects on metabolic tissues.
GLP-1 Receptor
GLP-1R activation also increases cAMP-related signaling. This pathway supports glucose-dependent insulin secretion and influences appetite and gastrointestinal signaling. The response depends on the tissue where the receptor is expressed.
Glucagon Receptor
GCGR activation influences cAMP signaling, particularly in the liver, where glucagon regulates pathways involved in glucose and energy metabolism.
These pathways are related but not identical. Retatrutide’s research interest lies in activating all three receptor systems with a single molecule, rather than targeting only one pathway.
The discovery study “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” characterized retatrutide’s activity across these three receptor systems.
How Retatrutide Targets Three Receptors
Retatrutide is a triple receptor agonist that activates GIP, GLP-1, and glucagon receptors through one peptide molecule.
| Receptor | Major Function |
| GIPR | Signaling of insulin and nutrients |
| GLP-1R | Glucose, appetite, and gut signaling |
| GCGR | Glucose and energy metabolism |
The biological functions of the three pathways differ from each other, but their combined activation forms the basis of retatrutide’s unique pharmacological profile. Research shows that retatrutide has activity at all three receptors, with its relative receptor activity carefully studied during drug development.
The study “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” established the triple-agonist profile of retatrutide and supported further clinical research.
In simple words: retatrutide brings three metabolic signaling pathways together in one investigational peptide.
Mechanism of Retatrutide
The mechanism of action of retatrutide is derived from the action of GIP, GLP-1, and glucagon receptors. Each of them provides a unique metabolic signal.
- The GIP receptor supports nutrient sensing and glucose-dependent insulin signaling.
- The GLP-1 receptor controls glucose homeostasis, appetite, and gastrointestinal signaling.
- The glucagon receptor regulates hepatic glucose metabolism and energy homeostasis.
The scientific interest is in interactions of these pathways when one peptide molecule activates them. Instead of studying each receptor separately, scientists investigate how they interact and provide their effects on glucose metabolism, appetite, and energy balance together.
The finding was reported in the paper entitled “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.”
However, activation of receptors does not suggest that all three pathways have the same effect. It is important because their activity, tissue distribution, signaling potency, and pharmacokinetics determine the overall pharmacological properties of retatrutide.
If you want to learn the Retatrutide mechanism of action in detail, you can read our article Retatrutide Mechanism Explained: How Triple Agonist Peptides Work
Retatrutide, Semaglutide and Tirzepatide: A Quick Comparison
Retatrutide differs from other incretin-based compounds because it activates three receptors instead of one or two. This difference shows why researchers describe it as a triple agonist.
| Peptide | GIPR | GLP-1R | GCGR |
| Semaglutide | No | Yes | No |
| Tirzepatide | Yes | Yes | No |
| Retatrutide | Yes | Yes | Yes |
The main action of Semaglutide is on the GLP-1 receptor. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide brings together glucagon receptor activity along with both these incretin pathways.
Pharmacologically, the main difference is this additional receptor target. The study, “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept,” confirmed the activity of retatrutide at all three receptor systems.
This is a useful comparison for understanding receptor pharmacology. It does not mean that one compound is better than another in general. They each have a different molecular profile and history of research.
The Glucagon Receptor: What is Special About It?
The GCGR makes retatrutide unique by giving it an additional characteristic that separates it from GLP-1 and GIP/GLP-1 receptor agonists.
The hormone glucagon regulates glucose metabolism. Activation of the receptor may lead to increased gluconeogenesis and changes in the metabolism of stored energy.
During retatrutide studies, the effect on the GCGR is analyzed together with effects on the GIPR and GLP-1R receptors. Scientists research the effects on metabolic signaling in a combination, rather than in isolation of the glucagon mechanism.
The paper “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” determined the importance of GCGR activity for retatrutide’s pharmacological profile.
It also explains why retatrutide cannot be considered just another GLP-1 peptide. The activity of GCGR adds a different metabolic pathway for scientists to explore.
Receptor Balance: Why Does It Matter?
It is not just the activation of three receptors that makes retatrutide worth researching. Receptor balance between GIPR, GLP-1R, and GCGR is equally important.
Each receptor performs its specific functions, and the signaling pathways of receptors can affect the same metabolic processes. Scientists investigate many different aspects, such as the potency of a receptor, intensity of signaling, tissue expression, and pharmacokinetic properties, in order to estimate retatrutide.
A study entitled “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” characterized the activity of retatrutide on all three receptors. It was an important step to set the pharmacological balance and develop a triple agonist.
In other words, three receptors do not necessarily mean three equal biological responses. The biological effect depends on the degree of activation of these signaling pathways and interaction between them in different tissues.
Retatrutide: Regulatory/Research Status
Retatrutide continues to be an experimental drug developed by Eli Lilly. Research has been advancing from early pharmacological studies to late Phase 3 clinical trials.
The Phase 2 trial “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” in the New England Journal of Medicine gave clinical data backing further development of the drug.
Since then, Eli Lilly has advanced retatrutide into the multi-study Phase 3 TRIUMPH program, which tests retatrutide in a variety of obesity and metabolic disorders.
Retatrutide is not approved by the FDA. Safety, efficacy, and long-term clinical outcomes of retatrutide continue to be studied through clinical research.
This is significant information for readers interested in research. Currently, there are grounds to continue researching the receptor activities of GIP, GLP-1, and glucagon. Retatrutide should not be described as an FDA-approved drug because it remains investigational.
FAQs
1. What are the three receptors targeted by retatrutide?
Retatrutide activates the GIP receptor, GLP-1 receptor, and glucagon receptor. This three-receptor activity gives it its triple-agonist classification.
2. Is retatrutide only a GLP-1 agonist?
Retatrutide activates the GLP-1 receptor, but it is not a selective GLP-1 agonist. It also targets GIP and glucagon receptors.
3. What is the importance of the GIP receptor?
GIP receptors participate in nutrient sensing, insulin signaling, and metabolic regulation. GIP is one of the body’s naturally occurring incretin hormones.
4. What does the glucagon receptor do?
The glucagon receptor helps regulate hepatic glucose production and energy metabolism. Its activity is an important part of retatrutide’s triple-receptor mechanism.
5. What is the difference between retatrutide and tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors, while retatrutide activates GIP, GLP-1, and glucagon receptors.
6. How is retatrutide different from semaglutide?
Semaglutide primarily targets the GLP-1 receptor. Retatrutide targets three receptor systems.
7. Is retatrutide approved by the FDA?
No. Retatrutide remains investigational and has not received FDA approval.
8. Why do we call retatrutide a triple agonist?
It is called a triple agonist because one peptide molecule has pharmacological activity at three receptor targets: GIPR, GLP-1R, and GCGR.
Concluding Remarks
Retatrutide represents a distinct approach to metabolic research because it activates three receptor pathways through one peptide molecule. Its activity at the GIP, GLP-1, and glucagon receptors creates a pharmacological profile that differs from single and dual receptor agonists.
Research shows that each pathway contributes a different biological signal. GIPR relates to nutrient and insulin signaling, GLP-1R influences glucose and appetite pathways, and GCGR participates in glucose and energy metabolism.
The discovery study “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept” established the foundation for studying this three-receptor approach. Later clinical trials expanded the evidence base.
Retatrutide remains investigational, so ongoing research is essential for understanding its long-term pharmacology, safety, and clinical potential.
